Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

Open access
Corey, G. Ralph, Kabler, Heidi, Mehra, Purvi, Gupta, Sandeep, Overcash, J. Scott, Porwal, Ashwin, Giordano, Philip, Lucasti, Christopher, Perez, Antonio, Good, Samantha, Jiang, Hai, Moeck, Greg, O'Riordan, William·2014·New England Journal of Medicine

Abstract

BACKGROUND: Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and prolonged half-life allow for single-dose treatment. METHODS: We conducted a randomized, double-blind trial in which adults with acute bacterial skin and skin-structure infections received either a single intravenous dose of 1200 mg of oritavancin or a regimen of intravenous vancomycin twice daily for 7 to 10 days. Three efficacy end points were tested for noninferiority. The primary composite end point was defined as cessation of spreading or reduction in lesion size, absence of fever, and no need for administration of a rescue antibiotic 48 to 72 hours after administration of oritavancin. Secondary end points were clinical cure 7 to 14 days after the end of treatment, as determined by a study investigator, and a reduction in lesion size of 20% or more 48 to 72 hours after administration of oritavancin. RESULTS: The modified intention-to-treat population comprised 475 patients who received oritavancin and 479 patients who received vancomycin. All three efficacy end points met the prespecified noninferiority margin of 10 percentage points for oritavancin versus vancomycin: primary end point, 82.3% versus 78.9% (95% confidence interval [CI] for the difference, -1.6 to 8.4 percentage points); investigator-assessed clinical cure, 79.6% versus 80.0% (95% CI for the difference, -5.5 to 4.7 percentage points); and proportion of patients with a reduction in lesion area of 20% or more, 86.9% versus 82.9% (95% CI for the difference, -0.5 to 8.6 percentage points). Efficacy outcomes measured according to type of pathogen, including methicillin-resistant Staphylococcus aureus, were similar in the two treatment groups. The overall frequency of adverse events was also similar, although nausea was more common among those treated with oritavancin. CONCLUSIONS: A single dose of oritavancin was noninferior to twice-daily vancomycin administered for 7 to 10 days for the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens. (Funded by the Medicines Company; SOLO I ClinicalTrials.gov number, NCT01252719.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1310422

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 305

Metadata

Authors
Corey, G. R., Kabler, H., Mehra, P., Gupta, S., Overcash, J. S., Porwal, A., Giordano, P., Lucasti, C., Perez, A., Good, S., Jiang, H., Moeck, G., & O'Riordan, W.
Venue
New England Journal of Medicine
Published
2014-06-05
Volume
370
Issue
23
Pages
2180-2190
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2161621663
Cited by
305
References
20
FWCI
28.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. https://app.cochat.ai/papers/10.1056/nejmoa1310422
The paper
Corey, G. R., Kabler, H., Mehra, P., Gupta, S., Overcash, J. S., Porwal, A., Giordano, P., Lucasti, C., Perez, A., Good, S., Jiang, H., Moeck, G., & O'Riordan, W. (2014). Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1310422

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.